Analyst Consensus ?
ConsensusBuy26 ratings
Bullish1973.1%
Neutral726.9%
Bearish00.0%
US Foods Holding Corp. · USFD · FY2026 Q3 · Calendar Q4 2026
US Foods lifts FY2026 outlook as share gains and AI support growth
US Foods’ Q3 narrative supports a growth case built on market-share gains, service expansion and productivity tools, while the outlook still depends on sustained case-volume growth and effective cost recovery. Management’s confidence is constructive, but not evidence that the consumer and cost risks have passed.
Why did USFD fall 2.8% after beating EPS estimates in FY2026 Q3?
Research this report with FN2. Free to start; review your question before sending.
Reported Before market openNYSEConsumer Defensive
$23.11B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.26
Consensus $1.25
EPS surprise
+0.8%
Reported versus consensus
Reported revenue
$10.40B
Consensus $10.58B
Revenue surprise
-1.7%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-2.8%
Event window
SPY move
-4.4%
Same window
Abnormal move
+1.6%
Stock minus SPY
Volume
2.7×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
USFDSPY benchmark
Ask FN2 about USFD FY2026 Q3
Choose a question to continue your research
Why did USFD fall 2.8% after beating EPS estimates in FY2026 Q3?What changed in USFD's guidance and outlook in FY2026 Q3?Give me the bull and bear case for USFD after FY2026 Q3 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with Q2, when management reaffirmed its FY2026 outlook, the Q3 call described updated full-year growth targets. Management also said AI tools contributed to adjusted EBITDA and set a higher target for next year; Prime Line adds a specialty assortment and integration opportunity. The reported quarter’s revenue was below consensus while EPS was modestly above it, so the results were mixed against estimates.
Guidance delta
Management updated FY2026 guidance to 4–5% sales growth, 9–11% adjusted EBITDA growth and 18–20% adjusted EPS growth, according to the supplied call analysis. The prior-quarter analysis said guidance had been reaffirmed; no further prior numerical guidance is supplied here.
Key takeaways
- Q3 net sales rose 2.1%; adjusted EBITDA increased 10% and adjusted EPS increased 18%, according to the supplied call analysis.
- Management cited share gains across independent restaurants, healthcare and hospitality.
- Pronto expansion, Prime Line integration and AI tools are central parts of the growth narrative.
- The scorecard shows EPS slightly above consensus and revenue below consensus.
- Management updated its FY2026 growth outlook despite macroeconomic headwinds.
Management priorities
- Extend Pronto Next Day into five additional markets by year-end.
- Scale Scout AI and Visit Assistant across the business.
- Integrate Prime Line and continue pursuing tuck-in acquisitions.
- Pursue automation pilots, safety initiatives and vendor-management savings.
Follow USFD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$106.75Current
$40Low
$90.45Average
$127High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 6, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Nov 5, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 15, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Sep 29, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 12, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 7, 2026 |
| UBS | Buy | Buy | Maintain | Aug 7, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 7, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 7, 2026 |
| BTIG | Buy | Buy | Maintain | Aug 7, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Feb 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Feb 13, 2026 |
| Truist Securities | Buy | Buy | Maintain | Feb 14, 2025 |
| Jefferies | Buy | Buy | Maintain | Dec 16, 2024 |
| Deutsche Bank | Buy | Buy | Maintain | Aug 9, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | May 12, 2023 |
| Berenberg | Buy | Buy | Maintain | May 18, 2022 |
| CL King | Buy | Buy | Maintain | Mar 11, 2022 |
| Wolfe Research | Outperform | Outperform | Maintain | Sep 23, 2020 |
| CFRA | Hold | Buy | Downgrade | Mar 12, 2020 |
| Bank of America | Buy | Buy | Maintain | Oct 3, 2019 |
| B of A Securities | Buy | Buy | Maintain | Oct 3, 2019 |
| Buckingham Research | Buy | Buy | Maintain | Sep 12, 2019 |
| Buckingham | Buy | Buy | Maintain | Sep 12, 2019 |
| RBC Capital | Sector Perform | Outperform | Downgrade | May 1, 2018 |
| Loop Capital | Hold | Hold | Maintain | Mar 16, 2018 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jun 20, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $106.76. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $111 | $98.45 | +4.0% | Oct 15, 2026 |
| Piper Sandler | Brian Mullan | $108 | $110.52 | +1.2% | Aug 12, 2026 |
| Morgan Stanley | Analyst unavailable | $107 | $107.14 | +0.2% | Aug 7, 2026 |
| BMO Capital | Kelly Bania | $120 | $107 | +12.4% | Aug 7, 2026 |
| UBS | Analyst unavailable | $127 | $106.97 | +19.0% | Aug 7, 2026 |
| BTIG | Analyst unavailable | $120 | $106.97 | +12.4% | Aug 7, 2026 |
| Guggenheim | John Heinbockel | $120 | $106.97 | +12.4% | Aug 7, 2026 |
| Morgan Stanley | Analyst unavailable | $103 | $101 | -3.5% | Jul 15, 2026 |
| Piper Sandler | Analyst unavailable | $88 | $81.84 | -17.6% | Jun 1, 2026 |
| BTIG | Analyst unavailable | $105 | $84.4 | -1.6% | May 11, 2026 |
| Morgan Stanley | Analyst unavailable | $94 | $100.43 | -11.9% | Feb 13, 2026 |
| UBS | Analyst unavailable | $117 | $100.11 | +9.6% | Feb 13, 2026 |
| Bernstein | Analyst unavailable | $106 | $100.27 | -0.7% | Feb 13, 2026 |
| Deutsche Bank | Lauren Silberman | $111 | $99.24 | +4.0% | Feb 13, 2026 |
| BMO Capital | Analyst unavailable | $115 | $101.98 | +7.7% | Feb 13, 2026 |
| BTIG | Analyst unavailable | $110 | $101.98 | +3.0% | Feb 13, 2026 |
| Guggenheim | John Heinbockel | $115 | $101.98 | +7.7% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $104 | $101.98 | -2.6% | Feb 13, 2026 |
| Piper Sandler | Brian Mullan | $103 | $101.98 | -3.5% | Feb 13, 2026 |
| Guggenheim | Analyst unavailable | $95 | $85.71 | -11.0% | Jan 20, 2026 |
| Morgan Stanley | Analyst unavailable | $92 | $85.71 | -13.8% | Jan 20, 2026 |
| Bernstein | Analyst unavailable | $95 | $76.26 | -11.0% | Oct 22, 2025 |
| Piper Sandler | Analyst unavailable | $85 | $77.41 | -20.4% | Sep 2, 2025 |
| Guggenheim | John Heinbockel | $88 | $79.32 | -17.6% | Aug 11, 2025 |
| Melius Research | Jacob Aiken-Phillips | $90 | $66.72 | -15.7% | Dec 18, 2024 |
| Piper Sandler | Brian Mullan | $75 | $63.14 | -29.7% | Nov 11, 2024 |
| BTIG | Peter Saleh | $72 | $61.81 | -32.6% | Oct 17, 2024 |
| Truist Financial | Jake Bartlett | $66 | $53.18 | -38.2% | Jun 6, 2024 |
| Deutsche Bank | Lauren Silberman | $72 | $54.45 | -32.6% | May 10, 2024 |
| BMO Capital | Kelly Bania | $62 | $54.56 | -41.9% | May 10, 2024 |
| Truist Financial | Jake Bartlett | $65 | $54.5 | -39.1% | May 10, 2024 |
| UBS | Mark Carden | $67 | $54.58 | -37.2% | May 10, 2024 |
| Bernstein | Jeffrey Bernstein | $64 | $54.8 | -40.0% | May 10, 2024 |
| BTIG | Peter Saleh | $62 | $53.5 | -41.9% | Mar 19, 2024 |
| UBS | Mark Carden | $64 | $49.79 | -40.0% | Feb 20, 2024 |
| Piper Sandler | Brian Mullan | $59 | $49.79 | -44.7% | Feb 20, 2024 |
| Guggenheim | Analyst unavailable | $45 | $33.04 | -57.8% | Aug 15, 2022 |
| Morgan Stanley | Analyst unavailable | $39 | $32.44 | -63.5% | Jul 18, 2022 |
| Barclays | Analyst unavailable | $34 | $32.01 | -68.2% | Jun 9, 2022 |
| Morgan Stanley | Analyst unavailable | $42 | $38.37 | -60.7% | Apr 22, 2022 |
| Deutsche Bank | Brian Mullan | $44 | $34.44 | -58.8% | Jan 21, 2022 |
| Wolfe Research | Greg Badishkanian | $41 | $35.65 | -61.6% | Nov 9, 2021 |
| Morgan Stanley | John Glass | $40 | $37.51 | -62.5% | Oct 13, 2021 |
| UBS | Mark Carden | $36 | $34.51 | -66.3% | Jul 29, 2021 |
Track every rating change on USFD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationUS Foods Holding Corp., operating primarily via its subsidiary, US Foods, Inc., is a key marketer and distributor within the United States foodservice market, offering an extensive selection of fresh, frozen, and dry food products alongside various non-food supplies. Its clientele is highly diversified, encompassing independent single and multi-location dining establishments, regional culinary ventures, national restaurant chains, institutional accounts such as hospitals, nursing homes, hotels, motels, country clubs, government and military entities, academic institutions, and certain retail businesses. Data from July 6, 2022, shows the company's operational infrastructure included 70 broadline facilities and 80 cash-and-carry sites. Formed in 2007, US Foods Holding Corp. transitioned from its previous designation, USF Holding Corp., to its current name in February 2016, and maintains its corporate headquarters in Rosemont, Illinois.
Consumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| TAP Molson Coors Beverage Company | FY2026 Q3 · Calendar Q4 2026 | +1.4% | -2.1% | Molson Coors cuts FY2026 outlook as costs and category softness weigh |
| MNST Monster Beverage Corporation | FY2026 Q3 · Calendar Q4 2026 | +0.3% | -1.9% | Monster’s international growth remains strong, while mix and input costs weigh on margins |
Latest beats and misses
Who reports nextBeat on EPS
- EOGFY2026 Q3 · November 5, 2026+8.9% EPS+2.2% move
- PBAFY2026 Q3 · November 5, 2026+13.5% EPS+1.0% move
- FNFFY2026 Q3 · November 5, 20260.0% EPS+6.6% move
- MTDFY2026 Q3 · November 5, 2026+3.6% EPS+4.8% move
- IAGFY2026 Q3 · November 5, 2026+16.7% EPS+4.6% move
- GMABFY2026 Q3 · November 5, 2026+55.6% EPS-4.3% move
Missed on EPS
- DKNGFY2026 Q3 · November 5, 2026-29.2% EPS-23.4% move
- WPMFY2026 Q3 · November 5, 2026-1.1% EPS+2.2% move
- CPTFY2026 Q3 · November 5, 2026-27.2% EPS-3.1% move
- VMRKFY2026 Q3 · November 4, 2026-425.6% EPS+2.4% move
- NTRAFY2026 Q3 · November 5, 2026-49.3% EPS-15.2% move
- TIGOFY2026 Q3 · November 5, 2026-40.8% EPS+2.6% move
Get the USFD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-05T20:06:49.210640+00:00
- FN2 earnings calendar · 2026-11-06T01:23:16.275024+00:00
- Polygon adjusted daily market bars · 2026-11-06T13:30:46.236829+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-06T13:30:46.234015+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-06. For educational purposes only; not investment advice.